| 前收市價 | 37.43 |
| 開市 | 37.00 |
| 買盤 | 36.55 x 800 |
| 賣出價 | 36.58 x 1000 |
| 今日波幅 | 36.51 - 37.00 |
| 52 週波幅 | 31.40 - 47.50 |
| 成交量 | |
| 平均成交量 | 493,787 |
| 市值 | 23.966B |
| Beta 值 (5 年，每月) | 0.67 |
| 市盈率 (最近 12 個月) | 35.98 |
| 每股盈利 (最近 12 個月) | 1.02 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 44.37 |
InvestorPlace3 Biotech Stocks You Better Be Buying on Each and Every Dip
Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks. Therefore, it is important to pick quality biotech stocks that have a competitive edge, solid financial position and clear growth strategy. Below are three biotech stocks that fit these criteria. These po
InvestorPlace3 Biotech Stocks That AI is Loving in July
Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks. I asked ChatGPT which biotech stocks it recommends for investment in July and it provided the following three companies. Let’s talk about these three AI recommended biotech stocks: Vertex (VRTX) Source: Pavel Kapysh / Shutterstock.com One of the companies ChatG
BenzingaFDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epkinly is being co-developed and co-commercialized by Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) as part of the companies' oncology collaboration. Epkinly features a dual-targeted approach continuously binding to T-cells and CD20+ lymphoma B-cell
